Hypothesis

Short‑term activation of NF‑κB‑inducing kinase (NIK) in CD8⁺ T cells, combined with pharmacological inhibition of the NLRP3 inflammasome, restores mitochondrial function and cytokine production in PD‑1⁺TIM‑3⁺ cells before they acquire additional co‑inhibitory receptors, thereby preventing progression to terminal exhaustion.

Mechanistic Rationale

NIK drives the non‑canonical NF‑κB pathway, which induces expression of PGC‑1α and SIRT3, promoting mitochondrial biogenesis and oxidative phosphorylation [3]. This metabolic rescue can revive IFN‑γ secretion even when PD‑1 and TIM‑3 remain on the surface. Conversely, NLRP3 activation releases IL‑1β and IL‑18, amplifying the SASP and reinforcing NF‑κB signaling that sustains exhaustion [6]. Inhibiting NLRP3 with MCC950 lowers IL‑1β, breaking the positive feedback loop between inflammasome activity and NF‑κB‑driven transcriptional programs that enforce T‑cell dysfunction.

Thus, the combination targets two arms of the NF‑κB/NLRP3 axis: NIK‑mediated metabolic reprogramming provides the energy needed for effector function, while NLRP3 blockade reduces inflammatory pressure that would otherwise re‑induce exhaustion signals.

Experimental Design

1. Model: Aged (20‑month‑old) C57BL/6 mice or human peripheral blood mononuclear cells from donors >65 years stratified by soluble PD‑1 (sPD‑1) levels [5].
2. Interventions:
   • Group A: NIK agonist (CD40L‑Fc) administered for 48 h.
   • Group B: NLRP3 inhibitor MCC950 administered concurrently with NIK agonist.
   • Group C: Vehicle control.
   • Group D: NIK agonist alone (to test sufficiency).
   • Group E: MCC950 alone (to test necessity of inflammasome suppression).
3. Readouts (day 3 and day 7 post‑treatment):
   • Flow cytometry for PD‑1, TIM‑3, TIGIT, LAG‑3 co‑expression.
   • Intracellular IFN‑γ, TNF‑α after PMA/ionomycin stimulation.
   • Seahorse assays for mitochondrial respiration and glycolysis.
   • SASP cytokines (IL‑6, IL‑1β) in supernatant.
   • Plasma sPD‑1 concentration as a pharmacodynamic biomarker.

Predicted Outcomes

If the hypothesis is correct, Group B will show:

• A significant reduction in the proportion of PD‑1⁺TIM‑3⁺TIGIT⁺LAG‑3⁺ cells compared with Groups A, C, D, and E.
• Restored IFN‑γ production in PD‑1⁺TIM‑3⁺ cells without downregulation of PD‑1 or TIM‑3 surface levels.
• Increased spare respiratory capacity and ATP production.
• Lower IL‑6 and IL‑1β levels, indicating attenuated SASP.
• A correlative drop in sPD‑1 that tracks the reversal of exhaustion.

Falsifiability

Failure to observe improved mitochondrial function or cytokine rescue in Group B despite adequate NIK activation and NLRP3 inhibition would falsify the hypothesis. Likewise, if PD‑1⁺TIM‑3⁺TIGIT⁺LAG‑3⁺ expansion proceeds unabated, or if sPD‑1 does not decline alongside functional recovery, the proposed mechanistic link between metabolic rescue and inflammasome suppression would be untenable.